The results from the study had not only confirmed that TAK1/NF-κB signaling, in line with mTOR, was negatively regulated by AMPK in ovarian cancer cells, but also provided an engaging example that AMPK activator could be potently exploited with a combined cocktail of TAK1 inhibitor 5Z-O and lipogenesis modulator Orlistat to exert synergistic anti-cancer effects in both in vitro 3D spheroids culture of ovarian cancer cells and in vivo metastatic dissemination of ovarian cancer. Here, MTOR is linked to ovarian carcinoma.